Benzinga | Mar 15, 2021 12:55PM EDT

Cantor Fitzgerald Maintains Overweight on Ocuphire Pharma, Raises Price Target to $20

Cantor Fitzgerald analyst Kristen Kluska maintains Ocuphire Pharma (NASDAQ:OCUP) with a Overweight and raises the price target from $15 to $20.